Direct-acting antiviral therapy for chronic hepatitis C

de Bruijne, J.

Citation for published version (APA):
de Bruijne, J. (2012). Direct-acting antiviral therapy for chronic hepatitis C

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
JF Bergmann*, J de Bruijne*, DM Hotho, RJ de Knegt, A Boonstra, CJ Weegink, AA van Vliet, J van de Wetering, SP Fletcher, LA Bauman, M Rahimy, JR Appleman, JL Freddo, HL Janssen, HW Reesink
Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
Alimentary Pharmacology and Therapeutics 2011;34(4):443-53

J de Bruijne, HW Reesink
Antivirale therapie specifiek gericht tegen chronische hepatitis C-virusinfectie
Tijdschrift voor Infectieziekten 2011;6(5):169-77

J de Bruijne, HW Reesink
Nieuwe antivirale therapie voor chronische hepatitis C
MAGMA 2011;4:113-115

PLM Jansen, J de Bruijne
Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C
Expert Opinion on Investigational Drugs 2012;21(1):111-8

J de Bruijne, JC Sullivan, TL Kieffer, M Botfield, B Shames, J Schinkel, R Molenkamp, C Weegink, HW Reesink
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment

DM Hotho*, J de Bruijne*, AM O’Farrell, T Boyea, J Li, M Bracken, X Li, D Campbell, HP Guler, CJ Weegink, J Schinkel, R Molenkamp, C Weegink, HW Reesink
Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated phase I study design
Antiviral Therapy 2012;17(2):365-375

A Boonstra, BS Liu, ZM Groothuismink, JF Bergmann, J de Bruijne, DM Hotho, BE Hansen, AA van Vliet, J van de Wetering, SP Fletcher, LA Bauman, M Rahimy, JR Appleman, JL Freddo, HW Reesink, RJ de Knegt, HL Janssen
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7
Antiviral Therapy 2012;17(4):657-667
K Dik, J de Bruijne, RB Takkenberg, MJ Roelofs, MJ Tempelmans, MG Dijkgraaf, HC Gelderblom, HW Reesink, JC Meijers, PJ Jansen, M Levi
Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C
Hepatology Research 2012;42(7):668-676

SJ Aronson, J de Bruijne, J Schinkel, CJ Weegink, M van der Valk, HW Reesink
New class of medicines for chronic hepatitis C
Nederlands Tijdschrift voor Geneeskunde 2012;156(10):A3840

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor
Antiviral Therapy 2012;17(4):633-42

J de Bruijne, J van de Wetering de Rooij, AA van Vliet, XJ Zhou, MF Temam, J Molles, J Chen, K Pietropaolo, JZ Sullivan-Bolyai, D Mayers, HW Reesink
First-in-human pharmacokinetics and antiviral activity of IDX375, a novel non-nucleoside hepatitis C virus polymerase inhibitor
Antimicrobial Agents Chemotherapy 2012;56(8):4525-8

XV Thomas*, J de Bruijne*, JC Sullivan, TL Kieffer, CKY Ho, S Rebers, M de Vries, HW Reesink, CJ Weegink, R Molenkamp, J Schinkel
Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir
PLoS ONE 2012;7(7):e41191

O Lenz*, J de Bruijne*, L Vijgen, T Verbinnen, C Weegink, H Van Marck, I Vandenbroucke, M Peeters, K Simmen, G Fanning, R Verloes, G Picchio, HW Reesink
Efficacy of re-treatment with TMC435, in combination therapy, for patients infected with hepatitis C virus genotype 1
Gastroenterology 2012, accepted

DM Hotho, J de Bruijne, M Spaan, MA Treitel, A Boonstra, RJ de Knegt, HLA Janssen, HW Reesink
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up Journal of Viral Hepatitis 2012, accepted

J de Bruijne*, X Thomas*, SP Rebers, CJ Weegink, MA Treitel, E Hughes, JF Bergmann, RJ de Knegt RJ, HLA Janssen, HW Reesink, R Molenkamp, J Schinkel
Long-term follow-up of genotypic changes in HCV-infected patients treated with narlaprevir, a potent NS3 protease inhibitor
Submitted

A de Niet, J de Bruijne, MJ Tempelmans Plat-Sinnige, RB Takkenberg, HW Reesink, RAW van Lier, EMM van Leeuwen
Upregulation of CXCR3+ expression on CD8+ T cells due to the pervasive influence of chronic hepatitis B and C infection
Submitted

*These authors made an equal contribution to this work